 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | Exosome-MSC Intravenous injection / Dermama Biotech Lab
New P2/3 trial: EXOMSC-COV19: Efficacy and Safety of EXOSOME-MSC Therapy to Reduce Hyper-inflammation In Moderate COVID-19 Patients (clinicaltrials.gov) - Jan 30, 2022
P2/3, N=60, Recruiting, Sponsor: Dermama Bioteknologi Laboratorium